Results 11 to 20 of about 1,034,952 (285)

Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion

Expert Opinion on Drug Delivery, 2020
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
W. Ceelen, Helena Braet, Gabrielle van Ramshorst, W. Willaert, K. Remaut   +4 more
semanticscholar   +2 more sources

Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]

, 2015
Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim, De Wever, Olivier, Descamps, Benedicte, Gremonprez, Félix, Izmer, Andrei, Vanhaecke, Frank, Vanhove, Christian   +6 more
core   +14 more sources

Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial

Journal of Clinical Oncology, 2023
PURPOSE In patients with peritoneal metastasis (PM) from gastric cancer (GC), chemotherapy is the treatment of choice. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are still being debated. This randomized, controlled,
B. Rau, Hauke Lang, Alfred Koenigsrainer, Ines Gockel, H. Rau, Hendrik Seeliger, Christian Lerchenmueller, D. Reim, Roger Wahba, Martin K Angele, S. Heeg, Tobias Keck, Arved Weimann, Stefan Topp, P. Piso, A. Brandl, Silke Schuele, Peter Jo, J. Pratschke, Sandra Wegel, A. Rehders, N. Moosmann, J. Gaedcke, Volker Heinemann, E. Trips, Markus Loeffler, P. Schlag, P. Thuss-Patience   +27 more
semanticscholar   +1 more source

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

Drugs, 2023
Malignancies of the peritoneal cavity are associated with a dismal prognosis. Systemic chemotherapy is the gold standard for patients with unresectable peritoneal disease, but its intraperitoneal effect is hampered by the peritoneal-plasma barrier ...
Niels A. D. Guchelaar, B. Noordman, S. Koolen, B. Mostert, E. Madsen, J. Burger, A. Brandt-Kerkhof, G. Creemers, I. D. de Hingh, M. Luyer, S. Bins, E. van Meerten, S. Lagarde, C. Verhoef, B. Wijnhoven, R. Mathijssen   +15 more
semanticscholar   +1 more source

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer

JAMA Surgery, 2022
Key Points Question Does hyperthermic intraperitoneal chemotherapy (HIPEC) after primary or interval cytoreductive surgery increase survival in patients with ovarian cancer?
M. Lim, Suk-Joon Chang, Boram Park, H. Yoo, C. Yoo, B. Nam, Sang-Yoon Park   +6 more
semanticscholar   +1 more source

The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.

JAMA Surgery, 2021
Importance Studies on the prognostic role of hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei (PMP) are currently not available.
S. Kusamura, F. Barretta, Y. Yonemura, P. Sugarbaker, B. Moran, E. Levine, D. Goéré, D. Baratti, E. Nizri, D. Morris, O. Glehen, A. Sardi, P. Barrios, F. Quénet, L. Villeneuve, A. Gómez-Portilla, I. D. de Hingh, W. Ceelen, J. Pelz, P. Piso, S. González-Moreno, K. van der Speeten, M. Deraco   +22 more
semanticscholar   +1 more source

Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study

Journal of Clinical Oncology, 2021
PURPOSE The purpose of this phase II study was to evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin for recurrent ovarian cancer during secondary cytoreductive surgery.
O. Zivanovic, D. Chi, Qin C Zhou, A. Iasonos, J. Konner, V. Makker, R. Grisham, Amy K Brown, S. Nerenstone, John P Diaz, E. Schroeder, C. Langstraat, V. Paroder, Y. Lakhman, Krysten Soldan, K. Su, G. Gardner, V. Andikyan, Jianxia Guo, E. Jewell, K. L. Long Roche, T. Troso-Sandoval, S. Lichtman, L. Moukarzel, K. Dessources, N. Abu-Rustum, C. Aghajanian, W. Tew, J. Beumer, Y. Sonoda, R. O'Cearbhaill   +30 more
semanticscholar   +1 more source

Simulating drug penetration during hyperthermic intraperitoneal chemotherapy

Drug Delivery, 2021
Hyperthermic intraperitoneal chemotherapy (HIPEC) is administered to treat residual microscopic disease after debulking cytoreductive surgery. During HIPEC, a limited number of catheters are used to administer and drain fluid containing chemotherapy (41 ...
Daan R Löke, R. F. Helderman, N. Franken, A. Oei, P. Tanis, J. Crezee, H. P. Kok   +6 more
semanticscholar   +1 more source

Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

Cureus, 2021
Hyperthermic intraperitoneal chemotherapy (HIPEC), along with optimal cytoreductive surgery, has been debated to be a viable option for the treatment of advanced epithelial ovarian cancer with peritoneal carcinomatosis.
Mona Mishra, Nilanchali Singh, P. Ghatage   +2 more
semanticscholar   +1 more source

Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer

JAMA Network Open, 2020
Key Points Question Is the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to primary cytoreductive surgery (PCS) associated with better outcomes for patients with stage III epithelial ovarian cancer?
Z. Lei, Yue Wang, Jiahong Wang, Ke Wang, Jun Tian, Ying Zhao, Lipai Chen, Jin Wang, Jiali Luo, M. Jia, Hong-sheng Tang, Qingjun He, Quanxing Liao, Xiansheng Yang, T. Guan, Li Wang, S. Cui   +16 more
semanticscholar   +1 more source